Sharon Klahre | Head, Investor Relations |
Michael Metzger | Chief Executive Officer |
Dr. Briggs Morrison | President and Head, R&D |
Keith Goldan | Chief Financial Officer |
Dr. Peter Ordentlich | Chief Scientific Officer |
Dr. Anjali Ganguli | Chief Business Officer |
Omari Baruti | Goldman Sachs |
Phil Nadeau | Cowen and Company |
Priyanka Grover | JPMorgan |
Ashiq Mubarack | Citi |
Brad Canino | Stifel |
Peter Lawson | Barclays |
Kalpit Patel | B. Riley Securities |
Bert Hazlett | BTIG |
Joel Beatty | Baird |
Good day, everyone, and welcome to the Syndax Fourth Quarter 2022 Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Thank you, operator. Welcome, and thank you all for joining us today for the review of Syndax's fourth quarter and full year 2022 financial and operating results.